Table 1.

Characteristics of tumors after siRNA/paclitaxel therapy

Cell lineGroupsIncidence (%) *No. nodulesPs for no. of nodules
SKOV3ip1Liposomes10016.3NS
Control siRNA10017.80.004
EphA2 siRNA1006
Paclitaxel + control siRNA1004.30.001
Paclitaxel + EphA2 siRNA902.2
HeyA8Liposomes1004.8NS
Control siRNA954.60.056
EphA2 siRNA852.8
Paclitaxel + control siRNA852.50.034
Paclitaxel + EphA2 siRNA801.5
  • * There was no significant difference (P < 0.05) between any two compared groups (by Student's t test) or all groups (by ANOVA) for incidence of tumor formation.